Troponin News and Research

RSS

Inclacumab reduces damage to heart muscle during angioplasty

A single dose of an investigational anti-inflammatory drug called inclacumab considerably reduces damage to heart muscle during angioplasty (the opening of a blocked artery), according to a recent international clinical trial spearheaded by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, affiliated with the University of Montreal.

11 Mar 2013

Potential stem cell therapy for Duchenne’s

Researchers have found that injecting aorta-derived stem cells into the hearts of dystrophin-deficient mice prevents the onset of dilated cardiomyopathy, raising hopes of a potential new treatment approach to prevent or reverse the condition in human Duchenne muscular dystrophy.

17 Jan 2013

Bleeding risk modifies perioperative beta-blocker benefits

Perioperative use of beta blockers seems to be beneficial unless patients experience heavy bleeding, in which case it may be detrimental, say researchers.

28 Nov 2012

Moderate exercise protects elderly hearts

The more exercise taken by individuals aged 65 years and older, the less likely biomarkers indicative of cardiac injury and new-onset heart failure are to increase, show US study findings.

26 Nov 2012

Anesthetic choice may not be critical in noncardiac surgery

The choice of general anesthetic does not appear to influence the risk for myocardial infarction in patients undergoing noncardiac surgery, report researchers.

14 Nov 2012

Simple biomarker model to predict heart failure risk

The most widely used models for predicting heart failure rely on a complex combination of lifestyle, demographic, and cardiovascular risk factor information.

8 Nov 2012

Changes in Troponin I protein can lead to cardiac muscle malfunction and precipitate heart failure

A new Johns Hopkins study has unraveled the changes in a key cardiac protein that can lead to heart muscle malfunction and precipitate heart failure.

13 Sep 2012

Study evaluates prognostic utility of novel biomarkers of cardiovascular stress

Critical Diagnostics announced today, Circulation, an American Heart Association Journal, released online the first study evaluating the power of ST2 to predict development of heart failure and other adverse outcomes in the general population titled, "Prognostic Utility of Novel Biomarkers of Cardiovascular Stress: The Framingham Heart Study".

5 Sep 2012

FSU researchers achieve significant benchmarks in alpha-tropomyosin study

Florida State University researchers led by physics doctoral student Campion Loong have achieved significant benchmarks in a study of the human cardiac protein alpha-tropomyosin, which is an essential, molecular-level component that controls the heart's contraction on every beat.

3 Sep 2012

Study finds decline in 30-day mortality of acute myocardial infarction with improved treatment

Improved treatment after acute myocardial infarction and less severe patient profile have reduced 30-day mortality over the past 15 years, according to research presented at ESC Congress 2012.

29 Aug 2012

Highly sensitive troponin assay shortens heart attack diagnosis

An algorithm that incorporates high-sensitivity cardiac troponin could allow accurate rule-in and rule-out of patients with acute chest pain within 1 hour of presentation, a study shows.

21 Aug 2012

Abbott to showcase new informatics and lab solutions at AACC annual meeting

Abbott will feature new solutions to improve data management and automation at this year's American Association for Clinical Chemistry (AACC) annual meeting, July 15-19, in Los Angeles, Calif. Solutions to further enhance efficiency and workflow in today's laboratories will be the focal point of the Abbott exhibit.

16 Jul 2012

Sustained ventricular arrhythmias in NSTE ACS rare but high-risk

Sustained ventricular fibrillation or tachycardia in patients admitted with non-ST-segment elevation acute coronary syndrome are uncommon but worsen patients’ prognosis markedly if they do develop, researchers report.

19 Jun 2012

Risk score may aid emergency heart failure decisions

A novel risk score may help physicians decide whether to admit or discharge patients who present to the emergency department with an acute episode of heart failure, say its developers.

12 Jun 2012

Roche files TnT-hs assay 510(k) submission with FDA for use on laboratory analyzers

Roche announced today that it has filed a 510(k) submission to the U.S. Food and Drug Administration (FDA) for a fully automated TnT-hs assay for use on Roche's full portfolio of laboratory analyzers.

From Roche Sequencing and Life Science 8 Jun 2012

New algorithm can help ED physicians to reduce number of heart failure deaths

Physicians can reduce the number of heart failure deaths and unnecessary hospital admissions by using a new computer-based algorithm developed at the Institute for Clinical Evaluative Sciences (ICES) that calculates each patient's individual risk of death. Published in the Annals of Internal Medicine, the algorithm improves upon clinical decision-making and determines whether or not a patient with heart failure should be admitted to hospital.

5 Jun 2012

Short spinning session can induce troponin T in healthy people

A short spinning session can trigger the same biochemical indications as a heart attack - a reaction that is probably both natural and harmless, but should be borne in mind when people seek emergency treatment for chest pain, reveals a study from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

7 Feb 2012

Chronic hyperglycemia may lead to cardiac damage

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health suggests that hyperglycemia (high blood sugar) injures the heart, even in patients without a history of heart disease or diabetes.

3 Feb 2012

Troponin I level test may help rule-out diagnosis of heart attack

For patients admitted to an emergency department with chest pain, use of a contemporary or highly sensitive test for levels of troponin I (a protein in muscle tissue) may help rule-out a diagnosis of heart attack, while changes in the measured levels of this biomarker at 3 hours after admission may be useful to confirm a diagnosis of heart attack, according to a study in the December 28 issue of JAMA.

28 Dec 2011

Promising results from Fate Therapeutics' ProHema Phase 1b trial on hematologic malignancies

Fate Therapeutics, Inc. announced today promising clinical results from a Phase 1b trial of ProHema (FT1050-enhanced umbilical cord blood) as part of double-umbilical cord blood (UCB) transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy.

14 Dec 2011